Cowen analyst Ritu Baral initiates coverage on Morphic Therapeutic (NASDAQ: MORF) with a Outperform rating.The analyst comments "We think ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE